| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Effect of Aspergillus niger prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Juan Pablo Stefanolo, Verónica Segura, Martina Grizzuti, Abel Heredia, Isabel Comino, Ana Florencia Costa, Roberto Puebla, María Paz Temprano, Sonia Isabel Niveloni, Gabriel de Diego, María E Oregui, Edgardo Gustavo Smecuol, Mauricio C de Marzi, Elena F Verdú, Carolina Sousa and Julio César Bai |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Asociación de Celíacos y Sensibles al Gluten de Madrid |
No. ACM 2020 |
| Research Committee Argentine Society of Gastroenterology |
No. 2020 |
|
| Corresponding Author |
Julio César Bai, MD, Emeritus Professor, Facultad de Medicina, Universidad del Salvador, 640 Rodriguez Peña, Buenos Aires C1051ABB, Argentina. jbai@intramed.net |
| Key Words |
Celiac disease; Aspergillus niger prolyl endoprotease; Gluten immunogenic peptides; Trial; Symptoms; Real-life trial |
| Core Tip |
In treated celiac disease (CeD) patients, exposure to gluten due to both voluntary and involuntary dietary lapses is prevalent and often leads to persistent symptoms despite adherence to a gluten-free diet. The potential of oral administration of Aspergillus niger prolyl endopeptidase (AN-PEP) in preventing the effects of inadvertent gluten exposure, as confirmed by gluten immunogenic peptide (GIP) stool excretion, and reducing CeD-specific symptoms in adults remains uncertain. Our study findings indicate that while AN-PEP did not significantly reduce overall GIP stool excretion, it notably lowered the prevalence of severe symptoms compared to the placebo arm. |
| Publish Date |
2024-03-21 11:37 |
| Citation |
Stefanolo JP, Segura V, Grizzuti M, Heredia A, Comino I, Costa AF, Puebla R, Temprano MP, Niveloni SI, de Diego G,Oregui ME, Smecuol EG, de Marzi MC, Verdú EF, Sousa C, Bai JC. Effect of Aspergillus niger prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet. World J Gastroenterol 2024; 30(11): 1545-1555 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i11/1545.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i11.1545 |
